Results 41 to 50 of about 2,720 (166)

In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales from patients with intra-abdominal infections: Results of the study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2020

Journal of Microbiology, Immunology and Infection, 2023
Background: Multi-drug resistant Enterobacterales is a growing health threat. Imipenem/relebactam and meropenem/vaborbactam, are not clinically used in Taiwan and the susceptibility is lack from routine laboratory tests.
Yu-Lin Lee, Wen-Chien Ko, Po-Ren Hsueh
doaj   +1 more source

Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections [PDF]

Journal of Antimicrobial Chemotherapy, 2019
Imipenem resistance in Pseudomonas aeruginosa most often entails loss of the 'carbapenem-specific' porin OprD; more rarely it reflects acquired carbapenemases. Loss of OprD only confers resistance to imipenem if AmpC β-lactamase is expressed, and we investigated whether this mechanism was overcome by relebactam, a developmental diazabicyclooctane β ...
Carolyne Horner, Shazad Mushtaq, David M Livermore, M Allen, D F J Brown, A P Johnson, C Longshaw, D M Livermore, A P MacGowan, N Woodford   +9 more
openaire   +3 more sources

Genomic Characterization of Imipenem- and Imipenem-Relebactam-Resistant Clinical Isolates of Pseudomonas aeruginosa

mSphere, 2021
The growing emergence and spread of carbapenem-resistant pathogens worldwide exacerbate the clinical challenge of treating these infections. Given the importance of carbapenems for the treatment of infections caused by Pseudomonas aeruginosa , this study aimed to investigate the underlying genomic properties of the ...
Mario López-Pérez, Jose M. Haro-Moreno, Carmen Molina-Pardines, Maria Paz Ventero, Juan Carlos Rodríguez   +4 more
openaire   +4 more sources

Successful Rapid Desensitization to Ceftazidime/Avibactam in a Patient With Cystic Fibrosis and Multidrug‐Resistant Pseudomonas aeruginosa Pneumonia: A Case Report

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Ceftazidime/avibactam (CAZ‐AVI) is an important therapeutic option for multidrug‐resistant (MDR) Pseudomonas aeruginosa infections; however, hypersensitivity reactions may preclude its use and create significant therapeutic challenges. We report a 21‐year‐old woman with cystic fibrosis and recurrent MDR P.
Zuoren Zhou, Jinqi Zhu, Ge Wu, Xi Kang, Qing Wang, Jie Liu, Yan Jiang   +6 more
wiley   +1 more source

Combination of Oral Doxycycline and Rifampin for Pan‐Drug Resistant Klebsiella pneumoniae Infection: A Case Report

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Pan‐drug resistant Klebsiella pneumoniae is a major therapeutic challenge, particularly when standard last‐line agents are unavailable or contraindicated. We report a 45‐year‐old man with multifocal osteomyelitis and persistent purulent wound discharge despite broad‐spectrum antibiotics, repeated debridement, and two sequential amputations ...
Ali Akbar Heydari, Sepideh Elyasi, Farshad Abedi   +2 more
wiley   +1 more source

Emergence of Ceftazidime‐Avibactam‐Induced KPC Variants (KPC‐25/127) in Intracranial Infection and Implications for Clinical Management

MicrobiologyOpen, Volume 15, Issue 4, August 2026.
Novel KPC‐25 and first‐reported KPC‐127 sequentially evolved in one patient under CAZ‐AVI pressure, distinct mutations remodel enzyme activity to drive differential multidrug resistance. ABSTRACT The emergence of novel Klebsiella pneumoniae carbapenemase (KPC) variants contributing to clinical treatment failure poses a substantial threat to public ...
Ke Lei, Ying Tian, Chaoliang Xiong, Jing Lei, Dong Chen, Xiangni Bai, Mohd H. Abdul‐Aziz, Jiao Xie, Zeshi Liu   +8 more
wiley   +1 more source

Phage Therapy as an Alternative Strategy Against Pseudomonas aeruginosa: A Narrative Review of Preclinical and Clinical Evidence

MicrobiologyOpen, Volume 15, Issue 3, June 2026.
Phage therapy shows promising efficacy against MDR, XDR, and PDR Pseudomonas aeruginosa infections across different models and administration routes. Evidence highlights reduced mortality, bacterial clearance, and synergy with antibiotics, while emphasizing the need for standardized protocols and advanced delivery systems to support clinical ...
Gustavo Aparecido da Cunha, Raine Piva Amaral, Ana Luisa Cauvila dos Santos, Bárbara Rafaela Ferreira Aio, Maria Fernanda Romboli Durante, Luiz Cosme Cotta Malaquias, Gabriel Magno de Freitas Almeida, Luiz Felipe Leomil Coelho   +7 more
wiley   +1 more source

The evolving role of structural biology in pharma: integration of X‐ray crystallography, cryo‐electron microscopy and beyond

Acta Crystallographica Section D, Volume 82, Issue 6, Page 587-602, June 2026.
This review describes how an integrated structural biology platform at Merck Sharp & Dohme LLC, Rahway, New Jersey, USA, combining X‐ray crystallography, cryo‐EM, MicroED and cryo‐ET, enables seamless three‐dimensional insights from molecular to cellular length scales.
Jill E. Chrencik, Hua-Poo Su, Yacob Gomez Llorente, Rachel L. Palte, Daniel J. Klein, Robert P. Hayes, Sadie P. Antine, Guilermo A. Asmar-Rovira, Nicole Bertoletti, Noel J. Byrne, Brittany L. Carroll, Ciro D. Cordeiro, Kaylynn Curfman, James Dutko, Michael J. Eddins, Thierry Fischmann, Barani Govindarajan, Corey W. Hecksel, Thu Ho, Kaspar Hollenstein, Mee Ra Hong, Alan Hruza, Andrii Ishchenko, Maru Jaime-Garza, Matt J. Jaremko, Hayley L. Knox, James Kostas, Harini Krishnamurthy, Ioannis Manolaridis, Cameron L. Noland, Andrea T. Partridge, Sangita B. Patel, Paul Reichert, John C. Reid, Catarina Felisberto-Rodrigues, Chitra A. Shintre, Jennifer M. Shipman, Elakkiya Tamilselvan, Morgan E. Walker, Susanne N. Walker, Renjing Wang, Katharine M. Wright, Tien-Jui Yen, Byung-Kuk Yoo, Sandra B. Gabelli   +44 more
wiley   +1 more source

In vitro activity of aztreonam in combination with relebactam against gram-negative pathogens producing various serine and metallo-β-lactamases

Journal of Global Antimicrobial Resistance
Objectives: Infections caused by carbapenemase-producing Gram-negative pathogens have become a significant global public health challenge due to limited treatment options.
Kengo Hayashi, Masahiro Suzuki, Yoshikazu Ishii, Yasufumi Matsumura, Kazuaki Matsumoto, Sho Saito, Yohei Doi   +6 more
doaj   +1 more source

Effects of Nacubactam and Its Metabolites on QTc Interval: A Pooled Analysis of Two Randomized Phase 1 Studies

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Nacubactam is a β‐lactamase inhibitor. Early‐phase studies with 1000/2000/4000/8000 mg nacubactam monotherapy were not powered to assess proarrhythmic risk. Therefore, this analysis pooled electrocardiogram data from two placebo‐controlled studies to quantify potential effects of nacubactam on cardiac repolarization.
Jun Morita, Sue McKendrick, Yuji Kumagai
wiley   +1 more source